North Chicago, Illinois-based biopharmaceutical company AbbVie Inc. said March 4 it will buy Sunnyvale, California-based Pharmacyclics, which specializes in cancer treatment, for $21 billion.
AbbVie is being represented by a team from Wachtell, Lipton, Rosen & Katz led by corporate partners Edward Herlihy, David Karp and David Lam. The team also includes antitrust partner Joseph Larson, executive compensation and benefits partner David Kahan, finance partners Joshua Feltman and Gregory Pessin and tax partner Joshua Holmes. Associates working on the deal include Michael Benn, Jeffrey Lee, Jenna Levine, Kate Napalkova, S. Iliana Ongun, Elina Tetelbaum, Lauren Thomas and Alisha Turak.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
